STOCK TITAN

ProPhase Labs Inc - PRPH STOCK NEWS

Welcome to our dedicated news page for ProPhase Labs (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProPhase Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProPhase Labs's position in the market.

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces the hiring of Jed Latkin as COO to help develop and grow its subsidiaries, including the commercialization of the BE-SMART esophageal cancer test in 2024. Mr. Latkin, a long-time industry veteran with a Columbia MBA, has been awarded a stock option to purchase up to 500,000 shares of the Company's common stock as an inducement to his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a successful transition to development stage, growth-oriented subsidiaries, with significant upside growth potential. The company aims for liquidity events in one or more subsidiaries in 2024 at implied valuations that may exceed the entire current market cap. Pharmaloz Manufacturing is on track to increase capacity from $10 million to over $75 million in 2024, with indications of demand for entire planned expansion. Nebula Genomics opens a new Whole Genome Sequencing lab in NY and sees significant demand. The company anticipates generating significant net profits by the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
-
Rhea-AI Summary
ProPhase Labs, Inc. will hold a conference call on November 9, 2023, to discuss its third-quarter results and provide a business update. The call will be hosted by CEO Ted Karkus. Participants can register for the call online or dial in. The call will be broadcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences earnings
Rhea-AI Summary
ProPhase Labs unveils expansion strategy for its subsidiary, Pharmaloz Manufacturing, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
Rhea-AI Summary
ProPhase Labs to present at The ThinkEquity Conference on October 19, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences
-
Rhea-AI Summary
ProPhase Labs reports Q2 financial results, highlights growth potential in genomics and biotech
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.89%
Tags
-
Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) provides an update on Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor developed by ProPhase BioPharma, Inc. The company is using advanced technology and machine learning to improve the efficacy of oncology therapy. They have partnered with Certis Oncology to determine the effectiveness of Linebacker in treating various types of cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
ProPhase Labs Inc

Nasdaq:PRPH

PRPH Rankings

PRPH Stock Data

117.65M
14.05M
22.06%
9.54%
1.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Garden City

About PRPH

prophase labs is a diversified natural health medical science company. for more information visit us at www.prophaselabs.com.